Neil Josephson - Nov 10, 2022 Form 4/A - Amendment Insider Report for Zymeworks Inc. (ZYME)

Role
Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Nov 10, 2022
Transactions value $
-$20,045
Form type
4/A - Amendment
Date filed
12/23/2022, 07:00 PM
Date Of Original Report
Nov 14, 2022
Previous filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Stock Options Exercise $0 +5.89K +53.31% $0.00 16.9K Nov 10, 2022 Direct F1
transaction ZYME Common Stock Sale -$20K -2.48K -14.62% $8.10 14.4K Nov 10, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -5.89K -33.33% $0.00 11.8K Nov 10, 2022 Common Shares 5.89K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.
F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5 The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.

Remarks:

This Amendment is being filed solely to include Exhibit 24 - Power of Attorney, which was inadvertently omitted in the Form 4 filed on November 14, 2022. Exhibit List - Exhibit 24 - Power of Attorney. On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.